Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serum Protein Profiling for Gemcitabine Sensitivity in Breast Cancer
NCT00212069Phase 2Completed
- Sponsor
- National University Hospital
- Start
- Mar 2004
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in breast cancer, sponsored by National University Hospital. Primary endpoint: Serum Protein Profile. Started Mar 2004; status: completed.
02
Drugs
gemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00212069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00212069.